Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

8.345 +0.775 (+10.24%)
Streaming Delayed Price Updated: 11:16 AM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 98,071
Open 7.640
Bid (Size) 8.360 (4)
Ask (Size) 8.400 (1)
Prev. Close 7.570
Today's Range 7.630 - 8.440
52wk Range 3.210 - 33.10
Shares Outstanding 41,009,442
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap: Fulcrum Therapeutics Q2 Earnings
  Fulcrum Therapeutics (NASDAQ:FULC) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Fulcrum Therapeutics Earnings Preview
  Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. 
Via Benzinga

Performance

YTD
-53.17%
-53.17%
1 Month
+58.95%
+58.95%
3 Month
+10.24%
+10.24%
6 Month
-25.42%
-25.42%
1 Year
-58.69%
-58.69%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
4 Analysts Have This to Say About Fulcrum Therapeutics
Via Benzinga
Analyst Ratings for Fulcrum Therapeutics
Via Benzinga
Recap: Fulcrum Therapeutics Q1 Earnings
Via Benzinga
10 Biggest Price Target Changes For Monday
Via Benzinga
91 Biggest Movers From Friday
Via Benzinga
Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Inflation Rate Accelerates to 8.6%
Via Benzinga
Looking Into Fulcrum Therapeutics's Return On Capital Employed
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Earnings Preview: Fulcrum Therapeutics
Via Benzinga
Fulcrum Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Via Benzinga
Fulcrum Therapeutics's Return On Capital Employed Overview
Via Benzinga
Fulcrum Therapeutics To Start Late-Stage Losmapimod Trial In Rare Muscle Wasting Disorder
Via Benzinga
Fulcrum Therapeutics: Q4 Earnings Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.